title: Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes.
abstract: OBJECTIVE
  The current staging system for lung cancer is not sufficient to accurately identify those patients with early-stage tumors who would benefit from postsurgery chemotherapy. The objective of this study was to validate a prognostic signature based on the expression of 5 RNA (ribonucleic acid) metabolism-related genes.
  
  
  METHODS
  Five lung cancer microarray datasets, 3 from adenocarcinomas and 2 from squamous cell carcinomas, were analyzed. Kaplan-Meier survival curves and Cox proportional hazards models were used to evaluate the relationship between the classifier and recurrence and survival.
  
  
  RESULTS
  Statistically significant differences in relapse-free survival and overall survival were observed when lung adenocarcinoma patients were divided into 3 risk groups. The prognostic information provided by the signature was independent from other demographic and disease variables, including stage. Significant differences in survival were observed between low- and high-risk groups in stage-IB patients: 5-year survival rates ranged from 83% to 100% in the low-risk groups, and from 30% to 71% in the high-risk groups, depending on the dataset. The RNA metabolism score additionally displayed an association with the benefit of adjuvant chemotherapy (P < .001), suggesting that those patients in the low-risk group are not good candidates for this treatment.
  
  
  CONCLUSIONS
  The RNA metabolism signature is a prognostic marker that may be useful for predicting survival and optimizing the benefit of adjuvant chemotherapy in patients with lung adenocarcinoma.
authors.affiliation: Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Pamplona, Spain; Department of Biochemistry and Genetics, School of Science, University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain. Electronic address: rpio@unav.es.
authors.forename: Ruben
authors.initials: R
authors.lastname: Pio
authors.affiliation: Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Spain.
authors.forename: Jackeline
authors.initials: J
authors.lastname: Agorreta
authors.affiliation: Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Spain.
authors.forename: Luis M
authors.initials: LM
authors.lastname: Montuenga
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism*; D000077192:Adenocarcinoma of Lung; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012334:RNA, Neoplasm / Q000235:genetics* / Q000378:metabolism*; D059467:Transcriptome
chemical_list: D012334:RNA, Neoplasm
keywords: RNA metabolism; adenocarcinoma; adjuvant chemotherapy; lung cancer; prognosis; squamous cell carcinoma